Can patients with hepatitis B take entecavir?
In general, "hepatitis B" refers to hepatitis B virus (HBV) infection. Patients with hepatitis B can take entecavir, which is a first-line antiviral drug used clinically for the treatment of chronic hepatitis B. It effectively suppresses HBV replication and slows the progression of liver damage. However, it must be used properly under medical supervision—patients should not self-medicate or discontinue treatment without guidance. The detailed analysis is as follows:
Entecavir belongs to the class of nucleoside analogs. It works by inhibiting the HBV DNA polymerase, thereby preventing viral replication within liver cells and reducing the viral load in the body. It is primarily indicated for patients with chronic hepatitis B who have detectable HBV DNA and elevated alanine aminotransferase (ALT) levels, those with cirrhosis accompanied by active HBV replication, and high-risk individuals requiring long-term viral suppression to reduce the risk of hepatocellular carcinoma.
Entecavir requires long-term administration; stopping the medication abruptly may lead to viral rebound and worsening liver function. Before starting treatment, patients should be evaluated for renal function abnormalities, and dosage adjustments are necessary for those with impaired kidney function. During therapy, regular monitoring of HBV DNA levels, liver function, and renal function is essential to assess both efficacy and safety.
Throughout the treatment process, patients should undergo regular follow-up tests of liver function and viral markers so that doctors can adjust the treatment plan accordingly. Additionally, maintaining a healthy lifestyle, avoiding alcohol consumption and excessive fatigue, can help improve treatment outcomes.